EA201690753A1 - COMBINATION INHIBITORS OF HISTONDEACETYLASE AND IMMUNOMODULATING MEDICINES - Google Patents

COMBINATION INHIBITORS OF HISTONDEACETYLASE AND IMMUNOMODULATING MEDICINES

Info

Publication number
EA201690753A1
EA201690753A1 EA201690753A EA201690753A EA201690753A1 EA 201690753 A1 EA201690753 A1 EA 201690753A1 EA 201690753 A EA201690753 A EA 201690753A EA 201690753 A EA201690753 A EA 201690753A EA 201690753 A1 EA201690753 A1 EA 201690753A1
Authority
EA
Eurasian Patent Office
Prior art keywords
histondeacetylase
immunomodulating
medicines
subject
combinations
Prior art date
Application number
EA201690753A
Other languages
Russian (ru)
Inventor
Стивен Норман Куэйл
Саймон Стюарт Джоунз
Кеннет С. Андерсон
Теру Хидесима
Original Assignee
Эситайлон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эситайлон Фармасьютикалз, Инк. filed Critical Эситайлон Фармасьютикалз, Инк.
Publication of EA201690753A1 publication Critical patent/EA201690753A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Настоящее изобретение относится к комбинациям, содержащим ингибитор ГДАЦ и иммуномодулирующее лекарственное средство, для лечения множественной миеломы у нуждающегося в этом субъекта. Указанные комбинации могут также содержать противовоспалительный агент, такой как дексаметазон. Также в настоящем изобретении предложены способы лечения множественной миеломы у нуждающегося в этом субъекта, включающие введение указанному субъекту эффективного количества одной из вышеуказанных комбинаций.The present invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for treating multiple myeloma in a subject in need thereof. These combinations may also contain an anti-inflammatory agent, such as dexamethasone. The present invention also provides methods for treating multiple myeloma in a subject in need thereof, comprising administering to said subject an effective amount of one of the above combinations.

EA201690753A 2013-10-11 2014-10-07 COMBINATION INHIBITORS OF HISTONDEACETYLASE AND IMMUNOMODULATING MEDICINES EA201690753A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361889640P 2013-10-11 2013-10-11
US201361911089P 2013-12-03 2013-12-03
PCT/US2014/059387 WO2015054175A1 (en) 2013-10-11 2014-10-07 Combinations of histone deactylase inhibitors and immunomodulatory drugs

Publications (1)

Publication Number Publication Date
EA201690753A1 true EA201690753A1 (en) 2016-07-29

Family

ID=52810182

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690753A EA201690753A1 (en) 2013-10-11 2014-10-07 COMBINATION INHIBITORS OF HISTONDEACETYLASE AND IMMUNOMODULATING MEDICINES

Country Status (17)

Country Link
US (2) US20150105358A1 (en)
EP (1) EP3054939A4 (en)
JP (4) JP2016532667A (en)
KR (1) KR20160060143A (en)
CN (1) CN105722507A (en)
AU (1) AU2014332147A1 (en)
CA (1) CA2926808A1 (en)
CL (1) CL2016000838A1 (en)
CR (1) CR20160200A (en)
EA (1) EA201690753A1 (en)
IL (1) IL244923A0 (en)
MX (1) MX2016004604A (en)
NI (1) NI201600051A (en)
PE (1) PE20161342A1 (en)
PH (1) PH12016500649A1 (en)
SG (1) SG11201602791RA (en)
WO (1) WO2015054175A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091213A2 (en) 2010-01-22 2011-07-28 Acetylon Pharmaceuticals Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
CN107011270A (en) 2010-11-16 2017-08-04 阿塞蒂隆制药公司 It is used as the pyrimidine hydroxyamide compounds and its application method of protein deacetylase inhibitor
JP2015515279A (en) 2012-04-19 2015-05-28 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Biomarkers identifying patients who respond to treatment and treatment of such patients
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
EP3054952B1 (en) * 2013-10-08 2022-10-26 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer
EP3055299B1 (en) * 2013-10-10 2021-01-06 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
AU2014332147A1 (en) * 2013-10-11 2016-05-05 Acetylon Pharmaceuticals, Inc. Combinations of histone deactylase inhibitors and immunomodulatory drugs
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
WO2015084905A1 (en) 2013-12-03 2015-06-11 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and immunomodulatory drugs
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
CA2954522A1 (en) 2014-07-07 2016-01-14 Acetylon Pharmaceuticals, Inc. Treatment of leukemia with histone deacetylase inhibitors
CA2969790A1 (en) 2014-12-05 2016-06-09 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine
CN107835810A (en) 2014-12-12 2018-03-23 瑞格纳西制药有限公司 Piperidine derivative as HDAC1/2 inhibitor
JP6816036B2 (en) 2015-06-08 2021-01-20 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Crystalline morphology of histone deacetylase inhibitors
AR105812A1 (en) 2015-06-08 2017-11-15 Acetylon Pharmaceuticals Inc METHODS FOR THE PREPARATION OF PROTEIN DEACETILASE INHIBITORS
WO2017143237A1 (en) * 2016-02-17 2017-08-24 Acetylon Pharmaceuticals, Inc. Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs
EP3445364A4 (en) 2016-04-19 2019-11-27 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia
JP7233220B2 (en) 2016-06-09 2023-03-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Methods of using HDAC inhibitors and BET inhibitors and pharmaceutical combinations thereof
EP3496751B1 (en) 2016-08-08 2022-10-19 Acetylon Pharmaceuticals Inc. Pharmaceutical combinations of histone deacetylase 6 inhibitors and cd20 inhibitory antibodies and uses thereof
KR102002581B1 (en) * 2016-10-04 2019-07-22 주식회사 종근당 Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer
WO2018098348A1 (en) 2016-11-23 2018-05-31 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a cd38 inhibitor and methods of use thereof
JP7090611B2 (en) * 2016-11-23 2022-06-24 アセチロン ファーマシューティカルズ インコーポレイテッド A pharmaceutical combination containing a histone deacetylase inhibitor and a programmed cell death ligand 1 (PD-L1) inhibitor and a method for using the same.
KR20240013098A (en) 2021-04-23 2024-01-30 테나야 테라퓨틱스, 인코포레이티드 HDAC6 inhibitors for use in the treatment of dilated cardiomyopathy
AU2022270657A1 (en) 2021-05-04 2023-11-16 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CA2627923C (en) * 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
WO2011091213A2 (en) * 2010-01-22 2011-07-28 Acetylon Pharmaceuticals Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
CN107011270A (en) * 2010-11-16 2017-08-04 阿塞蒂隆制药公司 It is used as the pyrimidine hydroxyamide compounds and its application method of protein deacetylase inhibitor
WO2013013113A2 (en) * 2011-07-20 2013-01-24 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
AU2014332147A1 (en) * 2013-10-11 2016-05-05 Acetylon Pharmaceuticals, Inc. Combinations of histone deactylase inhibitors and immunomodulatory drugs

Also Published As

Publication number Publication date
PH12016500649A1 (en) 2016-05-30
JP2021073314A (en) 2021-05-13
JP2019052171A (en) 2019-04-04
IL244923A0 (en) 2016-05-31
CL2016000838A1 (en) 2016-11-25
US20200323849A1 (en) 2020-10-15
EP3054939A1 (en) 2016-08-17
SG11201602791RA (en) 2016-05-30
JP2016532667A (en) 2016-10-20
PE20161342A1 (en) 2016-12-31
MX2016004604A (en) 2016-08-01
US20150105358A1 (en) 2015-04-16
NI201600051A (en) 2017-07-11
KR20160060143A (en) 2016-05-27
CR20160200A (en) 2016-08-29
CA2926808A1 (en) 2015-04-16
CN105722507A (en) 2016-06-29
EP3054939A4 (en) 2017-12-13
JP2024010118A (en) 2024-01-23
WO2015054175A1 (en) 2015-04-16
AU2014332147A1 (en) 2016-05-05
JP7403950B2 (en) 2023-12-25

Similar Documents

Publication Publication Date Title
EA201690753A1 (en) COMBINATION INHIBITORS OF HISTONDEACETYLASE AND IMMUNOMODULATING MEDICINES
EA201691155A1 (en) COMBINATION INHIBITORS OF HISTONDEACETYLASE AND IMMUNOMODULATING MEDICINES
EA201690406A1 (en) GRP94 SELECTIVE INHIBITORS AND METHODS OF THEIR APPLICATION
EA201591591A1 (en) COMPOUNDS OF CARBAZOLE APPLIED AS Bromodomain Inhibitors
EA201690734A1 (en) Bromodomain inhibitors
NI201600071A (en) AUTOTAXIN INHIBITOR COMPOUNDS
EA201890239A3 (en) FUMARATES AS A DEVELOPMENT AND THEIR APPLICATION IN THE TREATMENT OF DIFFERENT DISEASES
EA201790170A1 (en) THERAPEUTIC COMPOUNDS INHIBITORS
EA202092456A3 (en) COMBINATION THERAPY INCLUDING MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR TREATMENT OF VARIOUS TYPES OF CANCER
EA201490806A1 (en) COMBINED COMPOSITION OF TWO ANTI-VIRUS COMPOUNDS
EA201691421A1 (en) HETEROARILES AND THEIR APPLICATION
EA201692480A1 (en) PHARMACEUTICAL COMPOSITION
EA201690764A1 (en) INHIBITOR GRELIN-O-Aciltransferase
EA202090098A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
EA201500801A1 (en) BENZOHINOLONE INHIBITORS VMAT2
EA201690039A1 (en) RORC2 INHIBITORS AND METHODS OF THEIR APPLICATION
EA201490688A1 (en) 2 TİOPİRİMİDİNONI
EA201792496A1 (en) METHODS OF TREATMENT OF INFLAMMATION OR NEUROPATHIC PAIN
BR112015029462A8 (en) KINASE INHIBITORS
EA202091731A1 (en) AUTOTAXIN INHIBITORS AND THEIR APPLICATIONS
SA519410093B1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
EA201890364A1 (en) COMPOUNDS SUITABLE FOR INHIBITING ROR-GAMMA-t
EA201690783A1 (en) SUBSTANCES, PHARMACEUTICAL COMPOSITION AND METHODS OF APPLICATION IN THE TREATMENT OF INFLAMMATORY DISEASES
EA201791933A1 (en) INHIBITION OF OLIG2 ACTIVITY